FDA Clears Rheumatoid Dx Test by Bio-Rad, Axis-Shield | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories and Axis-Shield today announced the US Food and Drug Administration has cleared Bio-Rad's BioPlex 2200 Anti-CCP test for the early detection of rheumatoid arthritis.

The test, which is based on Axis-Shield's proprietary anti-CCP technology, is now being launched in the US. The test was made available outside the US earlier this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.